CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe (221935)

Study identification

• EU PAS number:
  EUPAS1000000299
• Study ID:
  1000000299
• Official title and acronym:
  CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe (221935)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  France

  Ireland

  Italy

  Spain

  United Kingdom
• Study description:
  This is a prospective observational cohort study. The study`s aim is to understand the population receiving CAB LA for PrEP in routine clinical practice, usage patterns, adherence, post marketing clinical effectiveness, discontinuations, and monitor for resistance among individuals who receive an HIV diagnosis while on CAB LA for PrEP.
• Study status:
  Ongoing

Research institutions and networks

Institutions

ViiV Healthcare

Networks

NEAT-ID Network

Study timelines

Date when funding contract was signed

Planned: 02/08/2023

Actual: 27/11/2023

Study start date

Planned: 30/08/2024

Actual: 23/08/2024

Date of final study report

Planned: 30/06/2030

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

ViiV Healthcare

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable